These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37468313)

  • 1. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibitors: Prospects in Connective Tissue Diseases.
    You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK1: Number one in the family; number one in inflammation?
    Spinelli FR; Colbert RA; Gadina M
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitor selectivity: new opportunities, better drugs?
    Virtanen A; Spinelli FR; Telliez JB; O'Shea JJ; Silvennoinen O; Gadina M
    Nat Rev Rheumatol; 2024 Oct; 20(10):649-665. PubMed ID: 39251770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.